entertainment -WSS

entertainment

author：explore 2025-09-30 18:20:29 - browse：4

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why medical students are struggling with mental health

focus

leisure time

WSS

World's first CRISPR

Anthos stroke drug appears safer than common blood thinner

Hospitals are piloting generative AI tools as regulators play catch

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

WATCH: Why do our ears pop?

WATCH: Why do our ears pop?

focus

entertainment

focus

Wildfire smoke exposes gaps in outdoor worker protections

Surprise medical billing ban raises prices elsewhere

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Anthos stroke drug appears safer than common blood thinner

Hollywood unions extend contract negotiations for actors

Hospitals look to new technology to keep health care workers safe

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Duchenne breakthrough therapy leaves behind pioneering families

Gain of function research would be limited under House proposal

explore

Hospitals look to new technology to keep health care workers safe

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

In 'major milestone,' FDA approves first cell therapy for solid tumors

Researchers tackle phage therapy hurdles for wider adoption

Ransomware attacks on hospitals: Study outlines patient impact

entertainment

focus

leisure time

knowledge